Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 6/20 | 0.53 |
| ▸ | CCKAR | P32238 | 4/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.51 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26444796 | 0.87 | MMP8 (0.56) | MMP1MMP2MMP8MMP9ERAP2 | |
| SCHEMBL23381126 | 0.82 | KISS1R (0.57) | MMP1MMP2MMP8MMP9CCKBR | |
| SCHEMBL26169713 | 0.78 | ECE1 (0.66) | MMP1MMP2MMP8MMP9MMP7 | |
| SCHEMBL16301507 | 0.78 | ECE1 (0.66) | MMP1MMP2MMP8MMP9MMP7 | |
| SCHEMBL13363679 | 0.78 | NPBWR1 (0.69) | NPBWR1 | |
| SCHEMBL22366982 | 0.77 | ERAP2 (0.67) | MMP1MMP2MMP8MMP9KISS1R | |
| SCHEMBL14886140 | 0.77 | IL23R (0.58) | KISS1RNPBWR1 | |
| SCHEMBL16507967 | 0.77 | IL23R (0.65) | KISS1RNPBWR1 | |
| SCHEMBL30596170 | 0.77 | ERAP2 (0.64) | MMP1CCKBRCCKARKISS1RERAP2 | |
| SCHEMBL21929715 | 0.77 | ACE (0.61) | MMP1MMP2MMP8MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | MMP1 3938/4885MMP2 1511/4885MMP8 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.